Le Lézard
Classified in: Health, Science and technology
Subject: FDA

VeraSci Receives FDA Grant to Support Qualification of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)


DURHAM, N.C., Sept. 5, 2019 /PRNewswire/ -- VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that they have received an FDA grant to conduct further research on the VRFCAT, their proprietary functional capacity assessment. The VRFCAT has recently been accepted into the FDA's COA Qualification Program as a measure of functional capacity for schizophrenia treatment trials. This project will use qualitative research methods to establish the clinical meaningfulness of this measure to patients, family members, and peer support specialists. Qualitative evidence supporting the clinical meaningfulness of the VRFCAT from patient and caregiver perspectives will help advance the VRFCAT through the FDA qualification process and is a key component of interest for payers and health care providers.

VeraSci logo (PRNewsfoto/VeraSci)

The VRFCAT is an eCOA task that simulates key instrumental activities of daily living (iADLS) in a realistic and interactive virtual environment. With demonstrated sensitivity to accepted measures of cognitive and functional deficits in multiple CNS disorders, the VRFCAT was developed in VeraSci's Innovation Lab to improve clinical trials by detecting functionally meaningful improvements in patients' everyday lives. The VRFCAT has numerous advantages over conventional assessments, and meets the highest psychometric standards, with strong support from industry sponsors, NIH and FDA as a functional co-primary outcome measure.

If you are interested in learning more about or demoing the VRFCAT, visit https://verasci.com/vrfcat/.

About VeraSci

Founded in 2004, VeraSci has a worldwide presence in clinical trial development, clinical and cognitive assessment and language services. VeraSci brings deep expertise, strategic innovation and unwavering commitment to every project, allowing each client to deliver data supporting innovative therapies.

For more information, press only:
PR Contact Name: Ashley Davis, Marketing Communications Manager
Phone number: 919-401-4642
Email: ashley.davis@verasci.com
Website: www.VeraSci.com

SOURCE VeraSci


These press releases may also interest you

4 jui 2020
From 9 July to 11 July 2020, the World Artificial Intelligence Conference (WAIC) will be held online due to the COVID-19 pandemic. Organized by the Shanghai Municipal People's Government, the annual conference's mission is to provide a global...

4 jui 2020
tourHQ, the global marketplace connecting travellers with tour guides around the world has been expanding its repertoire of Online Travel Experiences continuously since its launch in May 2020. These experiences allow clients to travel virtually from...

4 jui 2020
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...

4 jui 2020
Gilead Sciences, Inc. today announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed...

4 jui 2020
80.5% of BBB Accredited charities anticipate that their 2020 revenue will be lower than expected and are searching for new ways to engage Millennials and Generation Z donors.  Only 19% of people highly trust charities according to a Donor Trust...

4 jui 2020
Following its national expansion last year, VORO Real Estate has launched a new website with added features, reflecting the firm's rapid growth. This milestone is a major move for VORO on its mission to become an all-encompassing virtual brokerage....



News published on 5 september 2019 at 10:15 and distributed by: